Literature DB >> 22122406

Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model.

K Awa1, H Satoh, S Hori, Y Sawada.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Low-dose aspirin is widely used for prevention of thrombosis, but combined use of aspirin with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, reduces the antiplatelet effect of aspirin. However, there has been no report describing the effects of the timing of the ibuprofen dose on the degree of interaction between low-dose aspirin and ibuprofen. The purpose of this study was to predict the time-course of the antiplatelet effect of low-dose aspirin when ibuprofen is administered as a single dose or repeatedly in combination with aspirin at various time intervals.
METHODS: We simulated ex vivo platelet aggregation using a previously developed pharmacokinetic (PK)/pharmacodynamic (PD) model. RESULTS AND DISCUSSION: The antiplatelet effect of low-dose aspirin (81 mg) was predicted to be markedly reduced when ibuprofen (200 mg; the usual prescribed dose in Japan) was administered 1 h or less after aspirin, but not when it was administered more than 2 h after the administration of aspirin. Moreover, the administration of ibuprofen up to 12 h before aspirin completely abrogated the antiplatelet effect of aspirin. When ibuprofen (200 mg) was administered three times daily for 3 days (day 1 to day 3) on a background of continuous low-dose aspirin (81 mg) once daily, 2 h after aspirin, no reduction in the antiplatelet effect of aspirin was predicted on day 1, but a reduction is predicted from day 2, with no return to the initial level until more than 3 days after discontinuation of ibuprofen. A marked reduction in the antiplatelet effect of aspirin was also seen on the same schedule when the dosage of ibuprofen was 150 mg, which is the dose used in over-the-counter (OTC) preparations. WHAT IS NEW AND
CONCLUSION: This study indicates that the antiplatelet effect of low-dose aspirin can be markedly reduced with combined use of ibuprofen, depending on the timing of co-administration. As even the lower OTC dose of ibuprofen (150 mg) was enough to affect the antiplatelet effect of aspirin, health professionals should take into account patients' use of OTC ibuprofen when prescribing low-dose aspirin.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122406     DOI: 10.1111/j.1365-2710.2011.01313.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  10 in total

1.  Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.

Authors:  Johanne Brooks; Richard Warburton; Ian L P Beales
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

2.  [Use and potential risks of over-the-counter analgesics].

Authors:  A Freytag; R Quinzler; M Freitag; H Bickel; A Fuchs; H Hansen; S Hoefels; H-H König; K Mergenthal; S G Riedel-Heller; G Schön; S Weyerer; K Wegscheider; M Scherer; H van den Bussche; W E Haefeli; J Gensichen
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

3.  Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study.

Authors:  I L Meek; H E Vonkeman; J Kasemier; K L L Movig; M A F J van de Laar
Journal:  Eur J Clin Pharmacol       Date:  2012-08-14       Impact factor: 2.953

Review 4.  Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.

Authors:  José Pedro Henriques Patrício; Jorge Pinto Pereira Barbosa; Rui Miguel Monteiro Ramos; Nuno Filipe Pimenta Antunes; Pedro Carlos Santos de Melo
Journal:  Clin Drug Investig       Date:  2013-03       Impact factor: 2.859

Review 5.  Impairment of aspirin antiplatelet effects by non-opioid analgesic medication.

Authors:  Amin Polzin; Thomas Hohlfeld; Malte Kelm; Tobias Zeus
Journal:  World J Cardiol       Date:  2015-07-26

6.  Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.

Authors:  Mark Ruzov; Gilad Rimon; Oleg Pikovsky; David Stepensky
Journal:  Br J Clin Pharmacol       Date:  2015-12-15       Impact factor: 4.335

Review 7.  [DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain].

Authors:  W W Bolten; K Krüger; S Reiter-Niesert; D O Stichtenoth
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

8.  Drug-drug interaction discovery and demystification using Semantic Web technologies.

Authors:  Adeeb Noor; Abdullah Assiri; Serkan Ayvaz; Connor Clark; Michel Dumontier
Journal:  J Am Med Inform Assoc       Date:  2017-05-01       Impact factor: 4.497

9.  Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen.

Authors:  Dongseong Shin; Sook Joung Lee; Yu-Mi Ha; Young-Sim Choi; Jae-Won Kim; Se-Rin Park; Min Kyu Park
Journal:  Drug Des Devel Ther       Date:  2017-01-04       Impact factor: 4.162

10.  Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction.

Authors:  Kenta Shibata; Yuuki Akagi; Naofumi Nozawa; Hitoshi Shimomura; Takao Aoyama
Journal:  J Pharm Health Care Sci       Date:  2017-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.